Hyundai BioLand Co Ltd

Hyundai BioLand maintains a conservative capital structure with a debt-to-equity ratio of 0.08, significantly below the median for the Personal Products industry, and a current ratio of 3.26, indicating strong short-term liquidity. The company holds KRW 17.76 billion in cash and equivalents, representing 10.6% of total assets, and generates positive free cash flow of KRW 10.24 billion, supporting operational flexibility. Profitability metrics are weak, with a return on equity (ROE) of 0.19% and return on assets (ROA) of 0.15%, both below the industry median for ROE and ROA in the Personal Products sector. Gross margin stands at 41.0%, in line with the industry median, but operating margin is only 9.7%, reflecting high cost pressures or low pricing power. The company operates through four segments, with revenue concentration unclear from the input data. However, the Cosmetic Raw Material segment is explicitly named as a core business, suggesting a focus on high-margin, specialized ingredients. No geographic breakdown is provided, but the company is Korea-based, implying regional exposure to East Asian markets. Growth appears muted, with no forward-looking revenue guidance provided. Historical revenue of KRW 1.305 trillion is flat compared to prior periods, and no significant revenue acceleration is projected for the next fiscal year. Risk factors are minimal, with low liquidity and dilution risk scores. No immediate filing-based flags were detected, and the company has not issued new shares in the past 12 months. The absence of long-term debt (KRW 10.43 billion, or 6.2% of total assets) further reduces refinancing risk. No recent events, such as earnings calls, regulatory actions, or material filings, are disclosed in the input data. The company appears to operate with limited public visibility, relying on stable, low-growth operations in the raw materials space.